News

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...
Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...
A pharmacist holds boxes of Ozempic, a semaglutide injection drug made by Novo Nordisk, in Provo, Utah, on March 29, 2023.
New Report Covers PolyPid's Latest Developments; After Blockbuster Phase 3 Results in Surgical Infection Prevention, Could This Israeli Innovator Become Big Pharma’s Most Coveted Acquisition ...
Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).
Buying stocks that are trading at cheap valuations can set you up for some big gains later on. And it can minimize the risk ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...
Temasek spent $2 billion in April 2023 to raise its stake in Manipal to 59% from 18% in the biggest hospital sector deal ever ...
An article by Thai business platform ลงทุนแมน, recently shared by the Thai-Swedish Chamber of Commerce, sheds light on what ...